The immunogenicity , reactogenicity and safety of the @ - valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine ( PHiD-CV ) were evaluated in a cohort of Nigerian infants included in a study conducted in Mali and Nigeria ( ClinicalTrials.gov identifier : NCT@ ) .